Category Archives: "INforMS"

New Genentech data at 2021 AAN highlight impact & breadth of neuroscience portfolio
Evrysdi (risdiplam) 2-year FIREFISH Part 2 data show improvement in motor function in infants with Type 1 spinal muscular atrophy [...]
Janssen announces U.S. FDA approval of PONVORYâ„¢ (ponesimod)
Head-to-head pivotal clinical trial results showed PONVORYâ„¢ treatment led to nearly a third fewer annual relapses than [...]
FDA approval of intramuscular Plegridy (Peginterferon beta-1a)
Please be advised  of the recent approval by the FDA for intramuscular Plegridy (Peginterferon beta-1a) and an update to other sections [...]
Dr. Thrower discusses management, different types of multiple sclerosis fatigue
https://youtu.be/vtwauNrp8Jo Ben Thrower, MD, Medical Director, Andrew C. Carlos Multiple Sclerosis Institute, talks about different [...]
New data further reinforce Genentech’s Ocrevus (ocrelizumab) as effective treatment
7 5% of patients with relapsing-remitting multiple sclerosis (RRMS) and suboptimal response to prior treatment had no evidence of disease [...]
Genentech’s enspryng for Neuromyelitis Optica Spectrum Disorder
First and only FDA-approved subcutaneous treatment option for anti-aquaporin-4 antibody positive NMOSD that can be self-administered by a [...]
Mylan brings critical access to the multiple sclerosis community
HERTFORDSHIRE, England, and PITTSBURGH– August 19, 2020 – Mylan N.V. (NASDAQ: MYL) today announced the launch of the first [...]
A letter from Lemtrada regarding its home phlebotomy partner, EMSI
Good Day Lemtrada Patient – On July 3, 2020 Sanofi Genzyme was notified that our Lemtrada Home Phlebotomy Partner, Examination [...]
Inebilizumab approved for treatment of Neuromyelitis Optica Spectrum Disorder
The US FDA has approved inebilizumab for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults who are anti-aquaporin-4 [...]
Rebif® U.S. label includes pregnancy outcomes & lactation information
- Label update is based on data from a large register-based study, as well as other published studies over several decades - Multiple [...]

CMSC provides leadership in clinical research and education; develops vehicles to share information and knowledge among members; disseminates information to the health care community and to persons affected by MS.

Contact Us
Contact Us





I have a question about

First

Last




Feel Free To contact Us
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam molestie, tellus id pellen tesque feugiat, sem sem cursus orci, a placerat ante ante nec massa. consectetuer adipiscing elit.

+1-222-333-4444

New York, NY 10123 USA

Mon - Sat 9:00 AM